|
EP4649963A3
(en)
*
|
2014-04-14 |
2026-05-13 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CN109153644B
(zh)
|
2016-03-16 |
2022-10-21 |
H·李·莫菲特癌症中心研究有限公司 |
用以增强效应t细胞功能的针对cereblon的小分子
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
SI3526202T1
(sl)
|
2016-10-11 |
2025-04-30 |
Arvinas Operations, Inc. |
Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
JP7258009B2
(ja)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
抗増殖化合物及びその使用方法
|
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
EP3774804A1
(en)
|
2018-03-26 |
2021-02-17 |
Novartis AG |
N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
EP3778590A4
(en)
*
|
2018-04-09 |
2021-12-22 |
ShanghaiTech University |
ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
CN118344338A
(zh)
|
2018-04-23 |
2024-07-16 |
细胞基因公司 |
取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
EP3820532A4
(en)
|
2018-07-11 |
2022-04-06 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
JP2022507267A
(ja)
*
|
2018-11-13 |
2022-01-18 |
バイオセリックス， インコーポレイテッド |
置換イソインドリノン
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2019404022A1
(en)
|
2018-12-19 |
2021-07-08 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
BR112021011968A2
(pt)
|
2018-12-19 |
2021-09-08 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
US20220081435A1
(en)
*
|
2019-01-03 |
2022-03-17 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2020160193A2
(en)
*
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2020160192A1
(en)
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020160295A1
(en)
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3924054B1
(en)
*
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
*
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3932922A4
(en)
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
US12398139B2
(en)
*
|
2019-03-05 |
2025-08-26 |
Centre For Addiction And Mental Health |
Modulators of AMPA receptor signaling
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
|
EP3941607A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
TW202102497A
(zh)
|
2019-03-29 |
2021-01-16 |
瑞典商阿斯特捷利康公司 |
化合物及它們在治療癌症中之用途
|
|
CN111747924B
(zh)
*
|
2019-03-29 |
2023-11-10 |
华东师范大学 |
一类来那度胺/泊马度胺类似物及其应用
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
BR112021020775A2
(pt)
*
|
2019-04-18 |
2021-12-14 |
Hinova Pharmaceuticals Inc |
Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
JP2022533147A
(ja)
*
|
2019-05-17 |
2022-07-21 |
ヒノバ ファーマシューティカルズ インコーポレイテッド |
芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
BR112021024108A2
(pt)
|
2019-05-31 |
2022-03-22 |
Ikena Oncology Inc |
Inibidores de tead e usos dos mesmos
|
|
CN118027041A
(zh)
*
|
2019-05-31 |
2024-05-14 |
西藏海思科制药有限公司 |
一种btk抑制剂环衍生物及其制备方法和药学上的应用
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021022163A2
(en)
|
2019-07-31 |
2021-02-04 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2021023233A1
(zh)
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
EP4031247A1
(en)
*
|
2019-09-16 |
2022-07-27 |
Novartis AG |
Bifunctional degraders and their methods of use
|
|
AU2020348849A1
(en)
*
|
2019-09-19 |
2022-04-07 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
EP4034114A4
(en)
*
|
2019-09-23 |
2023-07-26 |
Accutar Biotechnology Inc. |
Novel ureas having androgen receptor degradation activity and uses thereof
|
|
EP3795570B1
(en)
*
|
2019-09-23 |
2022-02-23 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
JP7724394B2
(ja)
*
|
2019-10-09 |
2025-08-18 |
モンテ ローザ セラピューティクス アーゲー |
イソインドリノン化合物
|
|
MX2022004526A
(es)
|
2019-10-17 |
2022-07-21 |
Arvinas Operations Inc |
Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
|
|
US20210113557A1
(en)
*
|
2019-10-22 |
2021-04-22 |
Arvinas Operations, Inc. |
Methods of treating prostate cancer
|
|
CN110790750B
(zh)
*
|
2019-11-07 |
2021-09-21 |
郑州大学 |
一种邻苯二甲酰亚胺类选择性雄激素受体降解剂及其制备方法和用途
|
|
CN110746400B
(zh)
*
|
2019-11-07 |
2021-12-17 |
郑州大学 |
一种靶向雄激素受体的荧光探针及其制备方法
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
JP7629459B2
(ja)
|
2019-11-19 |
2025-02-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP7871189B2
(ja)
*
|
2019-12-17 |
2026-06-08 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質の動員および／または分解を調節する化合物
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
PH12022551482A1
(en)
|
2019-12-18 |
2023-11-29 |
Novartis Ag |
3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2021127443A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
AU2020414151A1
(en)
|
2019-12-23 |
2022-08-25 |
Jiangxi Jemincare Group Co., Ltd |
Protein degradation agent compound preparation method and application
|
|
US12528825B2
(en)
|
2020-01-29 |
2026-01-20 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
JP7815127B2
(ja)
|
2020-02-19 |
2026-02-17 |
ニューリックス セラピューティクス，インコーポレイテッド |
インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用
|
|
AU2021226514B2
(en)
*
|
2020-02-25 |
2023-10-19 |
Shanghaitech University |
Glutarimide skeleton-based compounds and application thereof
|
|
BR112022016901A2
(pt)
|
2020-02-26 |
2022-12-06 |
Cullgen Shanghai Inc |
Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
CN113387930B
(zh)
|
2020-03-11 |
2022-07-12 |
苏州开拓药业股份有限公司 |
一种双官能化合物及其制备方法和用途
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
CN115996918A
(zh)
*
|
2020-05-09 |
2023-04-21 |
阿尔维纳斯运营股份有限公司 |
制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
|
|
KR20230015934A
(ko)
*
|
2020-05-12 |
2023-01-31 |
아비나스 오퍼레이션스, 인코포레이티드 |
전립선암 치료 방법
|
|
WO2021231927A1
(en)
*
|
2020-05-14 |
2021-11-18 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
KR20230024328A
(ko)
|
2020-06-12 |
2023-02-20 |
상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 |
프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
CN113896711A
(zh)
*
|
2020-07-06 |
2022-01-07 |
北京诺诚健华医药科技有限公司 |
杂环类免疫调节剂
|
|
WO2022011205A1
(en)
*
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2022011204A1
(en)
*
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
WO2022019597A1
(ko)
*
|
2020-07-21 |
2022-01-27 |
주식회사 유빅스테라퓨틱스 |
안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
|
|
US20230302014A1
(en)
*
|
2020-08-04 |
2023-09-28 |
Oric Pharmaceuticals, Inc. |
Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN114181196A
(zh)
*
|
2020-09-14 |
2022-03-15 |
海思科医药集团股份有限公司 |
一种抑制并降解parp酶的化合物及其制备方法和药学上的应用
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2022066835A1
(en)
|
2020-09-23 |
2022-03-31 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
TW202221000A
(zh)
|
2020-09-30 |
2022-06-01 |
英屬開曼群島商百濟神州有限公司 |
用於降解ｅｇｆｒ之雙功能化合物及相關使用方法
|
|
WO2022087125A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
WO2022099117A1
(en)
|
2020-11-06 |
2022-05-12 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|
|
EP4240733A1
(en)
*
|
2020-11-06 |
2023-09-13 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN116529248B
(zh)
*
|
2020-11-25 |
2025-10-17 |
西藏海思科制药有限公司 |
一种苯环衍生物及其组合物和药学上的应用
|
|
CN114262319B
(zh)
*
|
2020-12-01 |
2023-05-05 |
南昌奥瑞药业有限公司 |
一类双功能分子、其制备方法及其应用
|
|
WO2022120355A1
(en)
*
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
US20220184078A1
(en)
|
2020-12-11 |
2022-06-16 |
Arvinas Operations, Inc. |
Methods of treating prostate cancer
|
|
US12152035B2
(en)
|
2020-12-30 |
2024-11-26 |
Industrial Technology Research Institute |
Androgen receptor binding molecule and use thereof
|
|
CN117242060B
(zh)
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
CN114853846A
(zh)
*
|
2021-02-04 |
2022-08-05 |
苏州国匡医药科技有限公司 |
一种雄激素受体降解剂及其应用
|
|
CN116847848A
(zh)
|
2021-02-10 |
2023-10-03 |
百济神州有限公司 |
Egfr降解剂和使用方法
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022187423A1
(en)
*
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
|
WO2022187419A1
(en)
*
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
AU2022240688B2
(en)
*
|
2021-03-17 |
2024-07-11 |
Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. |
Furan fused ring-substituted glutarimide compound
|
|
CA3211347A1
(en)
|
2021-03-19 |
2022-09-22 |
Erika Araujo |
Indazole based compounds and associated methods of use
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
EP4329746A4
(en)
*
|
2021-04-29 |
2025-03-19 |
Dana-Farber Cancer Institute, Inc. |
Phthalimido cereblon complex binders and transcription factor degraders and methods of use
|
|
EP4330251A4
(en)
|
2021-04-30 |
2025-03-05 |
BeiGene Switzerland GmbH |
EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
US20240287076A1
(en)
|
2021-05-05 |
2024-08-29 |
Biogen Ma Inc. |
Compounds for targeting degradation of bruton's tyrosine kinase
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
WO2022251588A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2022254362A1
(en)
|
2021-06-03 |
2022-12-08 |
Novartis Ag |
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
|
|
EP4361153A4
(en)
|
2021-06-25 |
2025-07-02 |
Korea Res Inst Chemical Tech |
NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
|
|
CA3224732A1
(en)
|
2021-07-07 |
2023-01-12 |
Kevin M. Guckian |
Compounds for targeting degradation of irak4 proteins
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
TW202317546A
(zh)
|
2021-07-09 |
2023-05-01 |
美商普萊克斯姆公司 |
調節ikzf2之芳基化合物及醫藥組合物
|
|
HUE070709T2
(hu)
|
2021-08-18 |
2025-06-28 |
Nurix Therapeutics Inc |
Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
|
|
WO2023025268A1
(zh)
*
|
2021-08-27 |
2023-03-02 |
苏州晶云药物科技股份有限公司 |
哒嗪甲酰胺类化合物的晶型及其制备方法
|
|
EP4395549A1
(en)
|
2021-09-01 |
2024-07-10 |
Oerth Bio LLC |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115772210A
(zh)
*
|
2021-09-08 |
2023-03-10 |
苏州开拓药业股份有限公司 |
硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途
|
|
CN113861186B
(zh)
*
|
2021-09-10 |
2023-08-25 |
浙江师范大学 |
基于异恶唑取代苯甲酰胺类衍生物及抗前列腺癌药物应用
|
|
US11981672B2
(en)
|
2021-09-13 |
2024-05-14 |
Montelino Therapeutics Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
CN113620931B
(zh)
*
|
2021-09-13 |
2023-06-09 |
中国海洋大学 |
一种雄激素受体抑制剂及其用途
|
|
US20240382603A1
(en)
*
|
2021-09-13 |
2024-11-21 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US20240376118A1
(en)
*
|
2021-09-13 |
2024-11-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US20240412330A1
(en)
|
2021-10-15 |
2024-12-12 |
University Of Tsukuba |
Information processing device, information processing method, and program
|
|
JP2024539269A
(ja)
*
|
2021-10-22 |
2024-10-28 |
グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド |
Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023093845A1
(zh)
|
2021-11-25 |
2023-06-01 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN115894450B
(zh)
*
|
2021-11-30 |
2023-09-12 |
山东如至生物医药科技有限公司 |
一种新型多环类化合物及其组合物和用途
|
|
AU2022405474B2
(en)
*
|
2021-12-08 |
2026-08-13 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
|
|
EP4455133A4
(en)
*
|
2021-12-24 |
2026-04-15 |
Suzhou Kintor Pharmaceuticals Inc |
MULTI-PROTEIN DEGRADING AGENT WITH AN IMIDE SKELETON
|
|
CA3240051A1
(en)
|
2021-12-30 |
2023-07-06 |
Beigene Switzerland Gmbh |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
TW202346281A
(zh)
|
2022-01-21 |
2023-12-01 |
瑞典商阿斯特捷利康公司 |
化合物以及它們在治療癌症中之用途
|
|
WO2023143427A1
(zh)
*
|
2022-01-27 |
2023-08-03 |
杭州领业医药科技有限公司 |
Arv-110的晶型及其制备方法和用途
|
|
KR20230140396A
(ko)
|
2022-03-23 |
2023-10-06 |
주식회사 대웅테라퓨틱스 |
핵 수용체의 저해 또는 분해를 유도하는 신규 화합물
|
|
CN119301111A
(zh)
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
JP2025512788A
(ja)
|
2022-03-25 |
2025-04-22 |
シェンチェン ファーマシン シーオー．，エルティーディー． |
Ｐｒｏｔａｃ化合物の医薬組成物及びその使用
|
|
KR20250004694A
(ko)
*
|
2022-04-06 |
2025-01-08 |
클루젠 (상하이), 인크. |
암 치료를 위한 조성물 및 방법
|
|
US12662467B2
(en)
|
2022-04-18 |
2026-06-23 |
BioThery X, Inc. |
Isoindolinones, pharmaceutical compositions, and therapeutic applications
|
|
TW202404643A
(zh)
|
2022-04-20 |
2024-02-01 |
大陸商同宜醫藥（蘇州）有限公司 |
化合物及用途
|
|
EP4511128A1
(en)
|
2022-04-20 |
2025-02-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
WO2023205481A1
(en)
|
2022-04-21 |
2023-10-26 |
Arvinas Operations, Inc. |
A combination for use in treating prostate cancer comprising arv-100 and abiraterone
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
WO2023242598A1
(en)
*
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
|
PE20251398A1
(es)
*
|
2022-06-30 |
2025-05-22 |
Bristol Myers Squibb Co |
Compuestos de degradacion de wee1 y usos de los mismos
|
|
WO2024002205A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same
|
|
CN119948021A
(zh)
*
|
2022-07-15 |
2025-05-06 |
西藏海思科制药有限公司 |
一种含氮杂环衍生物及其组合物和药学上的应用
|
|
JP2025524816A
(ja)
*
|
2022-07-20 |
2025-08-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ダロルタミドを含有する薬物インプラント及びその使用方法
|
|
CN115475164B
(zh)
*
|
2022-08-22 |
2024-06-04 |
西安交通大学 |
一种可降解PDGFR-β的蛋白降解靶向嵌合体及其制备方法和应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054952A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
KR20250067809A
(ko)
*
|
2022-09-14 |
2025-05-15 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
나프토푸란 치환 글루타르이미드계 화합물의 결정형, 제조방법 및 이의 용도
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
WO2024102810A1
(en)
|
2022-11-08 |
2024-05-16 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP4634184A1
(en)
|
2022-12-14 |
2025-10-22 |
Crossfire Oncology Holding B.V. |
Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
JP2026510359A
(ja)
|
2023-03-10 |
2026-04-02 |
アストラゼネカ・アクチエボラーグ |
アンドロゲン受容体を分解することができる二官能性化合物
|
|
WO2024201244A1
(en)
|
2023-03-24 |
2024-10-03 |
Assia Chemical Industries Ltd. |
Solid state forms of bavdegalutamide and process for preparation thereof
|
|
WO2024220926A1
(en)
|
2023-04-21 |
2024-10-24 |
Arvinas Operations, Inc. |
Use of an androgen receptor degrader protac for the treatment of prostate cancer
|
|
WO2024233696A1
(en)
|
2023-05-09 |
2024-11-14 |
Arvinas Operations, Inc. |
Bavdegalutamide for treating prostate cancer without ar l702h mutation
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2024278036A1
(en)
|
2023-05-24 |
2025-11-27 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Amorphous substance and crystal of dioxopiperidine compound or pharmaceutically acceptable salt thereof, preparation method, and use
|
|
WO2024246838A1
(en)
|
2023-05-31 |
2024-12-05 |
Beigene Switzerland Gmbh |
Compounds for the degradation of egfr kinase
|
|
EP4735451A1
(en)
|
2023-06-30 |
2026-05-06 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
CN122161821A
(zh)
*
|
2023-07-12 |
2026-06-05 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
CN117263865B
(zh)
*
|
2023-08-04 |
2026-03-27 |
南开大学 |
以6,6-二甲基双环[3.1.1]-2-甲胺为疏水基团的蛋白降解剂及其制备方法、药物组合物和应用
|
|
CN117126133B
(zh)
*
|
2023-08-14 |
2026-06-30 |
中国海洋大学 |
一种化合物及其用途
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
AU2024352092A1
(en)
|
2023-09-28 |
2026-04-09 |
Arvinas Operations, Inc. |
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2025085738A1
(en)
|
2023-10-18 |
2025-04-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2025083472A2
(en)
*
|
2023-10-20 |
2025-04-24 |
Seed Therapeutics Us, Inc. |
Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
|
|
WO2025085815A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Seed Therapeutics Us, Inc. |
Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
|
|
CN122228262A
(zh)
|
2023-11-02 |
2026-06-16 |
金橘生物科技公司 |
降解剂及其用途
|
|
WO2025108404A1
(zh)
*
|
2023-11-22 |
2025-05-30 |
广东东阳光药业股份有限公司 |
一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
|
|
WO2025114875A1
(en)
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
AU2024392985A1
(en)
|
2023-12-08 |
2026-06-04 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
CN122270449A
(zh)
|
2023-12-13 |
2026-06-23 |
百济神州(苏州)生物科技有限公司 |
通过将irak4抑制剂与e3连接酶配体缀合来降解irak4以及使用方法
|
|
WO2025152777A1
(zh)
*
|
2024-01-18 |
2025-07-24 |
海创药业股份有限公司 |
一种制备雄激素受体靶向降解化合物及其盐的方法
|
|
WO2025189056A1
(en)
|
2024-03-08 |
2025-09-12 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
CN118084737A
(zh)
*
|
2024-04-07 |
2024-05-28 |
江苏工程职业技术学院 |
4-(1-((叔丁氧基羰基)氨基)环丁基)苯甲酸的合成方法
|
|
WO2025226797A1
(en)
*
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Kred catalyzed ketoreduction of a cyclobutanone carbamic ester
|
|
WO2025235600A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Bristol-Myers Squibb Company |
Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds
|
|
CN118955474A
(zh)
*
|
2024-07-29 |
2024-11-15 |
浙江爱索拓标记医药科技有限公司 |
一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用
|
|
WO2026052822A1
(en)
|
2024-09-06 |
2026-03-12 |
Amphista Therapeutics Limited |
Tetrahydroisoquinoline compounds for targeted protein degradation
|
|
CN121735910A
(zh)
*
|
2024-09-27 |
2026-03-27 |
上海交通大学 |
一种模块化的分子胶化合物库及其构建方法和应用
|
|
WO2026129303A1
(zh)
*
|
2024-12-20 |
2026-06-25 |
上海壹迪生物技术有限公司 |
一种靶向雄激素受体蛋白降解的双功能化合物及其应用
|
|
KR20260106136A
(ko)
*
|
2024-12-30 |
2026-07-07 |
재단법인 대구경북첨단의료산업진흥재단 |
오토파지 매개 안드로겐 수용체 표적 분해용 신규 화합물 및 이의 의학적 용도
|